Bristol Myers Squibb & Co. (NYSE:BMY) on Wednesday released preliminary Phase 3 data showing that short- and long-term KarXT treatment reduced symptoms in patients experiencing psychosis associated with Alzheimer’s disease.
The company evaluated xanomeline and trospium chloride, known as KarXT, in the 12-week open-label period of its ADEPT-1 trial and the 52-week open-label extension ADEPT-3 study.
Across both trials, KarXT lowered clinician-observed scores for hallucinations, delusions, and overall disease severity while showing general tolerability and no new safety signals.
The company shared these first clinical findings from the ongoing Phase 3 ADEPT program during an oral presentation at the Clinical Trials on Alzheimer’s Disease Conference.
Treatment data across all ADEPT studies remain blinded, and descriptive analyses included only participants who completed or discontinued the open-label periods before data cutoff.
ADEPT-1 12-Week Open-Label KarXT Results
At the time of analysis, 273 of 320 enrolled participants, or 85.3%, completed the 12-week open-label lead-in period for ADEPT-1.
Patients receiving KarXT achieved a mean reduction of 12.0 points from a 14.4 baseline on the Neuropsychiatric Inventory-Clinician Hallucinations and Delusions (NPI-C H+D) scale (n=266).
Participants also recorded a mean drop of 1.9 points from a 4.5 baseline on the Clinical Global Impression-Severity score (n=267).
ADEPT-3 52-Week Extension Study Findings
The ADEPT-3 rollover study enrolls patients who finish the ADEPT-1, ADEPT-2, or ADEPT-4 trials.
Among 401 enrolled patients at data cutoff, 273, or 68.1%, finished the 52-week treatment period.
Through Week 52, patients saw a mean reduction of 5.1 points from an 8.9 open-label baseline on the NPI-C H+D scale (n=270) and a 0.8-point mean decrease from a 3.4 open-label baseline on the CGI-S score (n=277).
Bristol Myers Squibb gained approval for Cobenfy (KarXT), an oral medication for schizophrenia in adults, in September 2024. This marked the first new class of medicine in over three decades.
BMY Price Action: Bristol-Myers Squibb shares were down 2.10% at $60.06 on Wednesday, according to Benzinga Pro data.
Image via Shutterstock
